{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:36:11Z","timestamp":1649169371034},"reference-count":10,"publisher":"Japanese Urological Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2017,7,20]]},"DOI":"10.5980\/jpnjurol.108.145","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T22:29:52Z","timestamp":1532039392000},"page":"145-148","source":"Crossref","is-referenced-by-count":0,"title":["ADRENAL NEUROENDOCRINE CARCINOMA TREATED WITH LAPAROSCOPIC ADRENALECTOMY: A CASE REPORT"],"prefix":"10.5980","volume":"108","author":[{"given":"Taiki","family":"Kanbara","sequence":"first","affiliation":[{"name":"Department of Urology, Kochi Health Sciences Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Maehara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kochi Health Sciences Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Arata","sequence":"additional","affiliation":[{"name":"Department of Urology, Kochi Health Sciences Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Urology, Kochi Health Sciences Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","unstructured":"1) Lloyd RV: The neuroendocrine and paracrine systems. Diagnostic surgical pathology., 2, 561-570, 1994."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Lloyd RV: Overview of neuroendocrine cells and tumors. Endocrine pathology., 7, 323-328, 1996.","DOI":"10.1007\/BF02739840"},{"key":"3","unstructured":"4) Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO classification of tumours of the digestive system, World Health Organization, 2010."},{"key":"4","doi-asserted-by":"crossref","unstructured":"5) Moertel CG, Kvols LK, O&apos;Connell MJ and Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms, Cancer., 68, 227-232, 1991.","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I"},{"key":"5","doi-asserted-by":"publisher","unstructured":"6) Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET and Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer., 92, 1101-1107, 2001.","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V"},{"key":"6","doi-asserted-by":"publisher","unstructured":"7) Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M and Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British journal of cancer., 81, 1351-1355, 1999.","DOI":"10.1038\/sj.bjc.6690325"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Hainsworth JD, Spigel DR, Litchy S and Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol., 24, 3548-3554, 2006.","DOI":"10.1200\/JCO.2005.05.0575"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A and Papotti M: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy, Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc., 20, 1172-1182, 2007.","DOI":"10.1038\/modpathol.3800954"},{"key":"9","unstructured":"10) Osamura R, Hirabayashi H, Matsuda M and Itoh T, editors. Immunohistochmical Detection of SSTR2a in Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) and Response to Somatostatin Analogue (SA). LABORATORY INVESTIGATION: NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA., 2011."},{"key":"10","unstructured":"11) Osamura R, Matsuda M, Itoh T, Inomoto C, Kajiwara H, editors. Immunohistochemical Detection of Somatostatin Receptor 2a (SSTR2a) and mTOR in the Cases of Neuroendocrine Tumors (NETs) for Appropriate Biotherapy; Experience of a Large Series of Referred Cases. LABORATORY INVESTIGATION: NATUREPUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA., 2012."}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/108\/3\/108_145\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T01:32:04Z","timestamp":1571621524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/108\/3\/108_145\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.108.145","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}